Alternative Treatment Strategies for Perinatal Depression and Anxiety

2005 ◽  
pp. 182-193 ◽  
Author(s):  
Madeleine O’Higgins ◽  
Vivette Glover ◽  
Maria Corral
Keyword(s):  
Alternative Treatment ◽  
Perinatal Depression ◽  
Treatment Strategies ◽  
Depression And Anxiety

scholarly journals Dermatillomania: Strategies for Developing Protective Biomaterials/Cloth

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 341
Author(s):  
Priusha Ravipati ◽  
Bice Conti ◽  
Enrica Chiesa ◽  
Karine Andrieux
Keyword(s):  
Alternative Treatment ◽  
Negative Impact ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Primary Objective ◽  
Neuropsychiatric Disorder ◽  
Physical Barrier ◽  
Physical Treatment ◽  
Pubmed Database ◽  
Prevention Of Infections

Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual’s health and quality of life. The current treatment strategies focus on behavioral and pharmacological therapies that are not very effective. Thus, the primary objective of this review is to provide an introduction to SPD and discuss its current treatment strategies as well as to propose biomaterial-based physical barrier strategies as a supporting or alternative treatment. To this end, searches were conducted within the PubMed database and Google Scholar, and the results obtained were organized and presented as per the following categories: prevalence, etiology, consequences, diagnostic criteria, and treatment strategies. Furthermore, special attention was provided to alternative treatment strategies and biomaterial-based physical treatment strategies. A total of six products with the potential to be applied as physical barrier strategies in supporting SPD treatment were shortlisted and discussed. The results indicated that SPD is a complex, underestimated, and underemphasized neuropsychiatric disorder that needs heightened attention, especially with regard to its treatment and care. Moreover, the high synergistic potential of biomaterials and nanosystems in this area remains to be explored. Certain strategies that are already being utilized for wound healing can also be further exploited, particularly as far as the prevention of infections is concerned.

Abstract 17402: Single Nuclei RNA-sequencing of Human Hypertrophic Cardiomyopathy Myectomy Samples Reveals Common Novel Mechanisms of Pathogenesis and Potential Therapeutic Targets Regardless of Genotype

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Amy Larson ◽  
Hassan Rastegar ◽  
Gordon S Huggins ◽  
Ethan J Rowin ◽  
Martin S Maron ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hypertrophic Cardiomyopathy ◽  
Rna Sequencing ◽  
Alternative Treatment ◽  
Expression Patterns ◽  
Therapeutic Targets ◽  
Treatment Strategies ◽  
Ventricular Outflow Tract ◽  
Left Ventricular ◽  
Surgical Myectomy

Introduction: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disease, often resulting in left ventricular outflow tract obstruction, relieved by surgical myectomy. Current treatments are largely palliative and do not target the root causes. Understanding the molecular drivers of the disease could lead to alternative treatment strategies through identification of novel therapeutic targets. Methods: We performed single nuclei RNA-sequencing (snRNA-seq) on thousands of nuclei from 9 patient myectomy samples and septal tissue from 4 unused donor hearts selected randomly without regard to genotype to identify the cell populations and determine the gene expression patterns in individual cells. Each sample was processed individually using Seurat v3 for quality control and normalization. Next, all 13 samples were integrated into a combined dataset for clustering and differential gene expression analysis to identify markers specific to each cluster and to assign cell identities. Results: Our results revealed several clusters of cardiomyocytes with differences in sarcomeric and metabolic gene expression. Several fibroblast populations were also observed. Numerous genes were differentially expressed between the HCM and normal samples. For example, RARRES1 expression was observed in many of the fibroblast populations in the normal samples, but was absent in the HCM samples. RARRES1 is involved in regulating fatty acid metabolism and autophagy, both of which are altered in HCM. Additionally, expression of PLA2G2A was absent in the HCM samples but was present in almost every cell type in the normal controls. PLA2G2A is involved in suppression of RTK mediated hypertrophic signaling, impacts lipid signaling, and has tumor suppressor properties. Thus, both RARRES1 and PLA2G2A may represent novel targets in HCM. Conclusions: This approach reveals novel potential therapeutic targets within common final HCM pathological pathways independent of genotype that have the potential to guide development of alternative treatment strategies. Further analysis of larger datasets using this approach will likely identify even more common pathway targets and identify additional common mechanisms in the pathogenesis of obstructive HCM.

A cost-analysis of alternative treatment strategies for achalasia

1998 ◽  
Vol 114 ◽  
pp. A19 ◽  
Author(s):  
TF Imperiale ◽  
JB O'Connor ◽  
MF Vaezi ◽  
JE Richter
Keyword(s):  
Cost Analysis ◽  
Alternative Treatment ◽  
Treatment Strategies

scholarly journals Study protocol: a clinical trial for improving mental health screening for Aboriginal and Torres Strait Islander pregnant women and mothers of young children using the Kimberley Mum's Mood Scale

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Emma Carlin ◽  
Sarah J. Blondell ◽  
Yvonne Cadet-James ◽  
Sandra Campbell ◽  
Melissa Williams ◽  
...  
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Qualitative Methods ◽  
Real World ◽  
Torres Strait Islander ◽  
Perinatal Depression ◽  
Depression And Anxiety ◽  
Important Public Health ◽  
Torres Strait ◽  
Mood Scale

Abstract Background Improving the rates of, and instruments used in, screening for perinatal depression and anxiety among Aboriginal and Torres Strait Islander women are important public health priorities. The Kimberley Mum’s Mood Scale (KMMS) was developed and later validated as an effective and acceptable perinatal depression and anxiety screening tool for the Kimberley region under research conditions. Other regions have expressed interest in using the KMMS with perinatal Aboriginal and Torres Strait Islander women. It is, however, important to re-evaluate the KMMS in a larger Kimberley sample via a real world implementation study, and to test for applicability in other remote and regional environments before recommendations for wider use can be made. This paper outlines the protocol for evaluating the process of implementation and establishing the ‘real world’ validity and acceptability of the KMMS in the Kimberley, Pilbara and Far North Queensland in northern Australia. Methods The study will use a range of quantitative and qualitative methods across all sites. KMMS validation/revalidation internal consistency of Part 1 will be determined using Cronbach’s alpha. Equivalence for identifying risk of depression and anxiety compared to a standard reference assessment will be determined from receiver operating characteristic curves. Sensitivity and specificity will be determined based on these cut-points. Qualitative methods of phenomenology will be used to explore concepts of KMMS user acceptability (women and health professionals). Additional process evaluation methods will collate, assess and report on KMMS quality review data, consultations with health service administrators and management, field notes, and other documentation from the research team. This information will be reported on using the Dynamic Sustainability Framework. Discussion This project is contributing to the important public health priority of screening Aboriginal and Torres Strait Islander women for perinatal depression and anxiety with tools that are meaningful and responsive to cultural and clinical needs. Identifying and addressing barriers to implementation contributes to our understanding of the complexity of improving routine clinical practie. Trial registration The study was registered retrospectively on 15/05/2019 with the Australian and New Zealand Clinical Trial registry (ACTRN12619000580178).

Sign in / Sign up

Export Citation Format

Share Document